Your browser doesn't support javascript.
loading
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton, Rosalynd; Banuelos, Allison; Feng, Dongdong; Biswas, Tanuka; Kao, Kevin; McKenna, Kelly; Willingham, Stephen; Ho, Po Yi; Rosental, Benyamin; Tal, Michal Caspi; Raveh, Tal; Volkmer, Jens-Peter; Pegram, Mark D; Weissman, Irving L.
Afiliação
  • Upton R; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Banuelos A; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Feng D; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Biswas T; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Kao K; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • McKenna K; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Willingham S; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Ho PY; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Rosental B; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Regenerative Medicine and Stem Cell Research Center, Ben Gurion University of the Negev, 84105 Beer Sheva, Israel.
  • Tal MC; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Raveh T; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Volkmer JP; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305.
  • Pegram MD; Department of Medicine-Med/Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA 94305 mpegram@stanford.edu irv@stanford.edu.
  • Weissman IL; Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research, Stanford University, Stanford, CA 94305; mpegram@stanford.edu irv@stanford.edu.
Proc Natl Acad Sci U S A ; 118(29)2021 07 20.
Article em En | MEDLINE | ID: mdl-34257155
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antígeno CD47 / Anticorpos Monoclonais Humanizados / Trastuzumab / Antineoplásicos Imunológicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antígeno CD47 / Anticorpos Monoclonais Humanizados / Trastuzumab / Antineoplásicos Imunológicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article